IL6 and metabolic dysfunction-associated steatotic liver disease: Patients with ATD-driven MASLD, characterised by disproportionate inflammation and IL-6–mediated signalling, may benefit from strategies targeting inflammatory pathways or insulin resistance, whereas individuals with obesity-driven MASLD may respond more favourably to weight reduction and metabolic load modulation.